Eidos Therapeutics, Inc. (EIDX) financial statements (2022 and earlier)

Company profile

Business Address 101 MONTGOMERY STREET, SUITE 2550
SAN FRANCISCO, CA 94104
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments191,157157,147
Cash and cash equivalents191,157157,147
Receivables8534
Other undisclosed current assets4,6781,789
Total current assets:195,920158,970
Noncurrent Assets
Operating lease, right-of-use asset4,010
Property, plant and equipment1,259209
Other noncurrent assets2,631933
Total noncurrent assets:7,9001,142
TOTAL ASSETS:203,820160,112
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,4492,336
Accounts payable3,1511,956
Accrued liabilities433302
Employee-related liabilities1,86578
Debt554 
Deferred compensation liability143142
Due to related parties316256
Other undisclosed current liabilities3,9682,055
Total current liabilities:10,4304,789
Noncurrent Liabilities
Long-term debt and lease obligation20,703 
Long-term debt, excluding current maturities16,112 
Operating lease, liability4,591
Liabilities, other than long-term debt1,260316
Other liabilities95316
Derivative instruments and hedges, liabilities1,165 
Total noncurrent liabilities:21,963316
Total liabilities:32,3935,105
Stockholders' equity
Stockholders' equity attributable to parent171,427155,007
Common stock3837
Additional paid in capital274,494220,240
Accumulated deficit(103,105)(65,270)
Total stockholders' equity:171,427155,007
TOTAL LIABILITIES AND EQUITY:203,820160,112

Income statement (P&L) ($ in thousands)

12/31/2019
12/31/2018
Revenues26,691 
Cost of revenue
(Cost of Goods and Services Sold)
(2,500) 
Gross profit:24,191 
Operating expenses(64,778)(37,779)
Other undisclosed operating income136 
Operating loss:(40,451)(37,779)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
2,943(2,946)
Interest and debt expense(327) 
Net loss attributable to parent:(37,835)(40,725)
Other undisclosed net income available to common stockholders, basic 913
Net loss available to common stockholders, diluted:(37,835)(39,812)

Comprehensive Income ($ in thousands)

12/31/2019
12/31/2018
Net loss:(37,835)(40,725)
Comprehensive loss, net of tax, attributable to parent:(37,835)(40,725)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: